RedHill Biopharma (RDHL) Receivables (2016 - 2025)

RedHill Biopharma (RDHL) has 10 years of Receivables data on file, last reported at $3.3 million in Q4 2025.

• Receivables for Q4 2025 came in at $3.3 million, up 31.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (up 31.39% YoY), and the FY2025 annual result was $3.3 million, up 31.39% from the prior year.
• Receivables declined to $3.3 million in Q4 2025 per RDHL's latest filing, from $5.4 million in the prior quarter.
• Over five years, Receivables peaked at $36.0 million in Q3 2022 and troughed at $974000.0 in Q2 2024.
• A 5-year average of $18.0 million and a median of $23.3 million in 2021 frame the typical range for Receivables.
• The sharpest annual moves came in 2021 and 2023: Receivables surged 1257.37% in 2021, then plunged 92.49% in 2023.
• A 5-year view of Receivables shows it stood at $31.7 million in 2021, then climbed by 8.98% to $34.5 million in 2022, then sank by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024, then soared by 31.39% to $3.3 million in 2025.
• Business Quant data shows RDHL's Receivables at $3.3 million in Q4 2025, $5.4 million in Q2 2025, and $2.5 million in Q4 2024.